ALT5 Sigma Corporation (traded as "ALTS" on Nasdaq), a crypto asset trading and payment solutions company, announced the signing of a two-phase stock sale agreement worth up to $1.5 billion. The sale comprises both a Registered Direct Offering and a Private Placement. A total of 200 million shares or share equivalents will be sold at a price of $7.50 per share.
According to the company's statement, the lead investor in the private placement will be World Liberty Financial, Inc. (WLFI), with payment in WLFI tokens. This will give ALT5 approximately 7.5% of the total WLFI offering. The proceeds will be used as part of its cryptocurrency treasury building strategy. These funds will also be used to resolve existing litigation, pay down debt, strengthen operations, and provide general working capital.
Notable Names on the Board of Directors
Upon completion of the sale, there will be significant changes to the ALT5 board of directors. WLFI's Co-Founder and CEO, Zach Witkoff, will be appointed chairman of the board. Eric Trump, son of former US President Donald Trump, will be a board member. WLFI Co-Founder and COO, Zak Folkman, will serve as an observing member, while Matt Morgan will be appointed the company's chief investment officer (CIO).
According to ALT5 Sigma's statement, the sale was attended by leading global institutional investors and renowned crypto venture capital firms. The bids were determined at market price in accordance with Nasdaq rules. The process is expected to close around August 12, 2025.
The company's core financial technology activities include the ALT5 Pay and ALT5 Prime platforms. ALT5 Pay provides an award-winning payment infrastructure that enables global businesses to accept cryptocurrency payments, while ALT5 Prime enables institutional and individual investors to buy and sell crypto assets. The company has processed over $5 billion in crypto trading volume to date.
Shared Goal with WLFI: Growth in DeFi
World Liberty Financial operates as a protocol and governance platform that aims to make decentralized finance (DeFi) more accessible. Inspired by President Donald Trump's vision, WLFI aims to develop user-friendly DeFi tools.
ALT5 Sigma is also considering continuing its biotechnology operations as a separate company under the name "Alyea Therapeutics Corporation." However, these future plans and WLFI's strategy are subject to change depending on market conditions and regulatory processes.
This large-scale share sale and changes to the management team are seen as part of ALT5 Sigma's goal to strengthen its position in the crypto finance space. However, investors should be aware that, as emphasized in the company's official statements, various operational and market risks exist in implementing the planned strategies.
